Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging
NCT ID: NCT02796768
Last Updated: 2016-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
75 participants
OBSERVATIONAL
2014-12-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Screening for Developmental Dysplasia of the Hip in Newborns
NCT01818934
Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip
NCT02885831
Treatment for Mild Hip Dysplasia in Newborns
NCT00843258
Sonographic QUantification of Venous Circulation In the Preterm Brain
NCT04535375
Ultrasound, Peds Body Composition, and Neurodevelopmental Outcomes
NCT03479515
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HYPOTHESIS We hypothesize that automatically extracted bone/cartilage boundaries can provide useful information about DDH, enable more reliable and reproducible diagnoses, and reduce false diagnostic positives and negatives of DDH. Using 3D US may reveal clinically significant disease or dysplasia metrics that have the potential to change diagnostic procedures.
AIMS:
1. To determine if automatically extracted 3D bone/cartilage surfaces provide useful information (i.e., disease or dysplasia metrics) during the assessment of DDH and provide better visualization of the infant hip anatomy in comparison to regular 2D US-based DDH assessment.
2. To determine if diagnosing DDH using the 3D US images reduces the operator dependent false positive and false negative rates.
3. To determine if 3D US-based dysplasia metrics are as valuable in tracking disease progression as 2D US-based dysplasia metrics.
RESEARCH METHOD Parents and their infants that have been referred to the Orthopaedic Clinic at our institution for suspected or diagnosed DDH will be approached by the Orthopaedic Department's research staff to participate in the study. We are hoping to reach an n=75 as we expect 33% will be lost to follow up. Once eligible infants have been identified by clinical staff, the research staff will outline the study and will obtain informed consent. The parents will be informed of the four additional scan sessions that we would like to collect. Two separate orthopaedic surgeons will each perform one of the 3D and one 2D scan sessions, so as to assess inter-rater reliability. In order to assess intra-rater reliability, each scan session will consist of 2 successive scans.
A major goal of this study is to show that the automated image extraction/analysis by 3D US can reproduce the findings of an expert clinician trained in DDH diagnosis. The 3D images will be processed by using the confidence-weighted local-phase feature based image processing method. Accordingly, the dysplasia metrics can be directly compared between two specialists to determine the feasibility of this approach. Should this method prove to be efficacious, further study could potentially investigate whether this aspect of patient care could be made the responsibility of nurse practitioners.
A secondary goal of this study is to assess how 3D US compares to 2D US in tracking DDH progression. In order to investigate this, we will be giving parents the option to opt in to a second set of US scans if it is necessary for their infant to return to clinic for follow-up treatment. This will not be a mandatory criterion for inclusion into the study. However, as current clinical practice involves checking for DDH progression with 2D US scans, it will provide additional information that could be valuable for comparing the two scanning methods in tracking DDH progression. This option will be presented to parents in the form of a check box on the consent form for them to opt in if they so wish.
DATA ANALYSIS The reliability and accuracy of the 3D image-derived dysplasia metrics will be compared with the standard 2D B-mode US images in terms of variability within inter-rater and intra-rater measurements. For statistical significance of improvement in the diagnostic procedure, we require at least 50 infants with at least one affected hip or suspected affected hip with DDH. We have asked for a recruitment size of 75 as we believe that at least 33% will be lost to follow up. This will be achieved by performing a comparison study between the 2D and 3D US images collected for each patient at each clinic visit. Orthopaedic surgeons from our institution will be asked to identify important features from both (processed and un-processed) US images. For 2D images, the surgeons will measure α and ß angles and percent coverage of the femur. Intra- and inter-rater reliability will be calculated using kappa scores. For 3D images, profiles of α and ß angles and 3-dimensional percentage coverage of the femur (i.e. volume coverage instead of surface coverage), will be measured. These manual measurements will be compared to the measurements determined by automatic image extraction and analysis to test for improvement in diagnostic procedure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants
Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:
BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.
FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,
1 2D US scanning session of right and left hip by Specialist 1,
1 2D US scanning session of right and left hip by Specialist 2.
3D US Scanning
3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
2D US Scanning
2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3D US Scanning
3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
2D US Scanning
2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 0 to 4 months of age
Exclusion Criteria
* No diagnosis of DDH or not suspected of having DDH
* Other congenital hip abnormalities or genetic syndromes
* Patient/family does not live in the Lower Mainland
4 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
British Columbia Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kishore Mulpuri
Pediatric Orthopaedic Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kishore Mulpuri, MBBS, MS(Ortho), MHSc
Role: PRINCIPAL_INVESTIGATOR
Provincial Health Services Authority
Antony Hodgson, BASc, MASc, PhD
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Anthony Cooper, BSc, MBChB, FRCS
Role: PRINCIPAL_INVESTIGATOR
Provincial Health Services Authority
Rafeef Abugharbieh, BSc, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H14-01448
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.